目的: 检测EＲK 1、EＲK 2 及p－EＲK 1 /2 在结直肠癌中的表达，探讨其表达水平与临床指标的相关
性。方法: 收集2014－09～ 2016－09 在我院因结直肠腺癌行手术治疗的120 例病人的癌组织及癌旁组织，通过
qPCＲ 检测EＲK 1、EＲK 2 在癌和癌旁组织中的表达，通过IHC、Western blot 检测EＲK 1、EＲK 2 及p－EＲK 1 /2 蛋
白的表达，分析其与临床指标的相关性。结果: 与癌旁组织相比，EＲK 1、EＲK 2 mＲNA 在癌组织中显著高表达，
且与癌组织的分化程度相关。Western Blot 显示EＲK 1、EＲK 2 及p－EＲK 1 /2 蛋白在癌组织中均高表达。免疫
组化显示EＲK 1、EＲK 2 和p－EＲK 1 /2 在癌组织中的阳性率分别为85．0%、79．2%和81．7%，显著高于癌旁组织
( 分别为8．3%、10．8%和11．7%) 。癌细胞分化越差、TNM 分期越高以及有淋巴结转移者，其EＲK 1，EＲK 2 及p－
EＲK 1 /2 的蛋白表达量越高。结论: EＲK 1、EＲK 2 及p－EＲK 1 /2 在结直肠癌中显著高表达，与肿瘤的分化程
度、淋巴结转移和TNM 分期密切相关。EＲK 1 /2 和p－EＲK 1 /2 有望成为结直肠癌靶向治疗的关键靶点。

Objective: To explore the expression and clinical pathological significances of EＲKl，
EＲK 2 and p－EＲK 1 /2 by detecting expression of them in colorectal cancer tissues．Methods: 120 cases
of human colorectal cancer tissues and adjacent tumor tissues were collected in our hospital from
2014－09 to 2016－09．The mＲNA expression level was detected using reverse transcription PCＲ while
protein level was detected by Western blotting and immunohistochemistry( IHC) ， respectively．The correlations
between the protein level and clinical pathological significances were analyzed．Ｒesults: Compared
with colorectal mucosa tissues， the mＲNA expression of EＲKl and EＲK 2 in cancer tissues were
significantly increased， respectively，and related to the level of tumor differentiation．The protein level of
EＲK 1，EＲK 2 and p－EＲK 1 /2 showed by western blot were also significantly increased in cancer tissues．
The positive rate of EＲK 1，EＲK 2 and p－EＲK decided by IHC in cancer tissues were 85．0%、
79．2%and 81．7%， significantly higher than adjacent tumor tissues， respectively．The high expression of
these three proteins was significant correlation with the poor differentiation，high TNM staging，and lymphatic
metastasis．Conclusion: The significantly increased expression of EＲKl，EＲK 2 and p－EＲK 1 /2
in colonic and rectal cancer tissues are significantly related to differentiation of tumor cell， lymphatic
metastasis and clinical stage．EＲK 1 /2 and p－EＲK 2 may become potential therapeutic targets for the
treatment of colorectal cancer．

Ｒ730．3